2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Molecular Testing, Omics Technologies, Gene Editing, Treatment Considerations, Combination Therapy, Drug Development, Supportive Care, Therapy Sequence, Biological Therapies, Transplantation, Immunotherapy, Monoclonal Antibody Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Machine Learning, Biological Processes, Pathogenesis, Genomics, Hematopoiesis, Molecular Biology, Clinical Practice (Health Services and Quality), Clinical Guidelines, Patient Safety, Quality Improvement, Diseases, Bone Marrow Failure Syndromes, Aplastic Anemia, Immunology, Neutropenia, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Patient-Reported Outcomes, Real-World Evidence, Survivorship, Study Population, Human, Adult, Elderly
PAPER

5589 Genomic taxonomy of chronic myelomonocytic leukemia defines 16 molecular subsets with distinct clinicopathologic features, differentiation states, and outcomes

Sanam Loghavi, MD, Chong Wu2, Kelly Sharon Chien, MD3, Ian Bouligny, M.D.4, Rashmi Kanagal-Shamanna, MD5, Anuya Natu6, Mark Gurney7, Alexandre Bazinet, MD8, Danielle Hammond, MD9, Alex Bataller, MD, PhD10, Gautam Borthakur, MD11, Courtney DiNardo, MD, MSCE12, Tapan Kadia I, MD13, Farhad Ravandi, MD14, Naval Daver, MD15, Naveen Pemmaraju, MD16, Ghayas C. Issa, MD17, Sa Wang, MD18, Keyur P. Patel, MD19, Guilin Tang, MD, PhD,FACMG20, L. Jeffrey Medeiros, MD21, Terra Lasho, PhD22, Christy Finke, BS23, Aref Al-Kali, M.D.24, Clifford Csizmar, M.D., Ph.D.25, Hassan B Alkhateeb, M.D.26, Naseema Gangat, MBBS27, Abhishek Avinash Mangaonkar, MBBS28, Hagop Kantarjian, MD29, Guillermo Garcia-Manero, MD30, Mrinal M. Patnaik, MD, MBBS31, Guillermo Montalban-Bravo, MD32
1 MD Anderson Cancer Center, Houston, Texas, United States
2 MD Anderson Cancer Center, Houston, Texas, United States
3 MD Anderson Cancer Center, Houston, Texas, United States
4 MD Anderson Cancer Center, Houston, Texas, United States
5 MD Anderson Cancer Center, Houston, Texas, United States
6 Mayo Clinic, Rochester, United States
7 Mayo Clinic, Rochester, United States
8 MD Anderson Cancer Center, Houston, Texas, United States
9 MD Anderson Cancer Center, Houston, Texas, United States
10 MD Anderson Cancer Center, Houston, Texas, United States
11 MD Anderson Cancer Center, Houston, Texas, United States
12 MD Anderson Cancer Center, Houston, Texas, United States
13 MD Anderson Cancer Center, Houston, Texas, United States
14 MD Anderson Cancer Center, Houston, Texas, United States
15 MD Anderson Cancer Center, Houston, Texas, United States
16 MD Anderson Cancer Center, Houston, Texas, United States
17 MD Anderson Cancer Center, Houston, Texas, United States
18 MD Anderson Cancer Center, Houston, Texas, United States
19 MD Anderson Cancer Center, Houston, Texas, United States
20 MD Anderson Cancer Center, Houston, Texas, United States
21 MD Anderson Cancer Center, Houston, Texas, United States
22 Mayo Clinic, Rochester, United States
23 Mayo Clinic, Rochester, United States
24 Mayo Clinic, Rochester, United States
25 Mayo Clinic, Rochester, United States
26 Mayo Clinic, Rochester, United States
27 Mayo Clinic, Rochester, United States
28 Mayo Clinic, Rochester, United States
29 MD Anderson Cancer Center, Houston, Texas, United States
30 MD Anderson Cancer Center, Houston, Texas, United States
31 Mayo Clinic, Rochester, United States
32 MD Anderson Cancer Center, Houston, Texas, United States

Introduction: Chronic myelomonocytic leukemia (CMML) is a clonal hematopoietic stem-progenitor neoplasm with overlapping myelodysplastic/myeloproliferative features and clinical behavior distinct from MDS. Current prognostic models weigh individual mutations but do not capture the co-occurrence patterns and clonal architecture that shape disease phenotypes. We hypothesized that unsupervised integration of genomic data could resolve CMML into biologically coherent subsets with distinct clinical behavior and differentiation states. 

Methods: We evaluated 812 patients (pts) with CMML from MD Anderson (n=417) or Mayo Clinic (n=395) profiled by conventional karyotyping and next-generation sequencing of a panel of recurrently mutated myeloid genes (including TET2, SRSF2, ASXL1, RUNX1, SETBP1, EZH2, U2AF1, ZRSR2, SF3B1, CBL, NRAS, KRAS, PTPN11, CEBPA, DNMT3A, and TP53). Unsupervised clustering by partitioning around medoids (PAM) using gene mutations and recurrent cytogenetic lesions was performed to identify genomically informed clusters. The number of clusters (k=16) was selected to optimize cohesion and stability within clusters. Subsets were annotated by their dominant molecular features and compared for clinicopathologic characteristics, overall survival (OS), and leukemia-free survival (LFS) using Cox proportional-hazards models. Associations with bone marrow differentiation were assessed in 101 pts with detailed flow-cytometric immunophenotyping. Findings were validated in an independent IPSS-M CMML cohort. 

Results: Median age was 72 years (range 24-95) and 566 pts (70%) were male. 672 (83%) had CMML-1, and 140 (17%) had CMML-2; 376 (46%) had myeloproliferative CMML, 436 (54%) had myelodysplastic CMML. CPSS-Molecular risk was low in 82 (10%), intermediate-1 in 169 (21%), intermediate-2 in 275 (34%), and high in 187 (23%). Transformation to acute myeloid leukemia occurred in 123 (15%) patients. 

Unsupervised clustering identified 16 reproducible genomic subsets dominated by a genetic signature: TET2-SRSF2 (12.9%), CBL (11.9%), NRAS/KRAS-SRSF2 (10.6%), ASXL1-SRSF2 (10.3%), RASp (7.1%), TET2-RASp (6%), TET2 (6%), ASXL1 (5.8%), SRSF2/SF3B1 (5.3%), U2AF1-ASXL1 (5.3%), ASXL1-RASp (5%, enriched for -7, RUNX1, SETBP1), ASXL1-TET2 (4.4%), Normal karyotype (NOS, 3.8%), TET2-ZRSR2 (2.7%), TP53-complex (1.7%), and No events (0.9%), each with characteristic cytogenetic and clinical features. Subsets showed markedly divergent survival. The most favorable were TET2-SRSF2, TET2-RASp, TET2-ZRSR2, and isolated TET2 (including biallelic), with median OS of 68, 63, 56, and 55 months, respectively. The most adverse were TP53-complex (median OS 9 months; HR 4.37, 95% CI 2.14-8.89), ASXL1-RASp (monosomy 7/RUNX1/SETBP1) (21 months; HR 3.41, 2.01-5.78), RASp/KRAS (22 months; HR 2.90, 1.71-4.91), U2AF1-ASXL1 (23 months; HR 2.12, 1.21-3.70), and NRAS/KRAS-SRSF2 (29 months; HR 1.97, 1.24-3.14; all p<0.05) versus the reference subset (TET2-SRSF2). LFS mirrored these patterns, with the shortest LFS in TP53-complex (8 months; HR 5.55) and ASXL1-RASp (14 months; HR 4.13). Collapsing the subsets into three practical prognostic tiers preserved strong risk discrimination, with median OS of 68, 32, and 18 months across favorable-, intermediate-, and adverse-risk groups, respectively. 

Genomic subsets aligned with distinct differentiation states by flow cytometry: the ASXL1-RASp subset showed CD34+ progenitor expansion, RASp-mutant subsets showed higher bone marrow monocyte fractions, and SRSF2-mutant subsets displayed a CD34+ MEP/erythroid-biased phenotype. 

In the independent publicly available IPSS-M cohort, the subsets retained prognostic significance. TP53-complex defined the highest-risk group (HR 20.49, 8.42-49.83), and ASXL1-SRSF2 (HR 3.16, 1.59-6.27), NRAS/KRAS-SRSF2 (HR 3.22, 1.56-6.65), and U2AF1-ASXL1 (HR 3.14, 1.15-8.55) remained associated with adverse outcomes. 

Conclusions: A genomic taxonomy resolves CMML into 16 reproducible molecular subsets that integrate mutational co-occurrence and cytogenetics, correlate with distinct progenitor differentiation states, and stratify OS and LFS beyond individual lesions. These subsets condense into three prognostic tiers that provide a practical, clinically actionable framework for risk stratification, and their prognostic value was validated in an independent IPSS-M cohort. This taxonomy refines biologic classification and risk assessment in CMML and may inform subset-directed therapeutic strategies. 

Sanam Loghavi, MD: AbbVie - Honoraria; Arima Diagnostics - Honoraria; AstraZeneca - Honoraria; Syndax - Honoraria; Servier - Honoraria; Recordati - Honoraria; Invivoscribe - Honoraria; Tempus AI - Honoraria; caris diagnostics - Honoraria; Stemline - Honoraria; Celgene Corporation - Honoraria; Bristol Myers Squibb - Honoraria; Daiichi-Sankyo - Honoraria; Ground Truth Labs - Honoraria; Blueprint Medicine - Honoraria; Cogent Bio - Honoraria; Kura Oncology - Honoraria; Eli Lilly - Honoraria; Amgen - Research Funding; Ground Truth Labs - Research Funding; Astellas - Research Funding; Kura Oncology - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Arima Diagnostics - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Celgene Corporation - Consultancy (Includes expert testimony); Ground Truth Labs - Consultancy (Includes expert testimony); Blueprint Medicine - Consultancy (Includes expert testimony); Recordati - Consultancy (Includes expert testimony); Stemline - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); caris diagnostics - Consultancy (Includes expert testimony); Daiichi-Sankyo - Consultancy (Includes expert testimony); Tempus AI - Consultancy (Includes expert testimony); Invivoscribe - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Syndax - Consultancy (Includes expert testimony); Cogent Bio - Consultancy (Includes expert testimony)